Defence Therapeu Stock Price, News & Analysis

Defence Therapeutics (CSE: DTC, OTCQB: DTCFF) has announced that its Accum-002™ (AccuTOX®) exhibits dual functionality: acting as a tumor-killing molecule and an immune booster. AccuTOX® works synergistically with Immune Checkpoint Inhibitors (ICI) to enhance the immune system's capability to recognize and attack tumors. This is particularly significant as many solid tumors create a 'cold' environment that impedes immune response, leading to low success rates in ICI treatments. AccuTOX® transforms these cold tumors into 'hot' tumors, significantly increasing the effectiveness of ICIs. Preclinical studies showed a tenfold increase in efficacy when AccuTOX® is combined with various ICIs. Defence is open to partnerships to further develop this promising treatment.

Defence Therapeutics has announced that its second-generation ARM-X anti-cancer vaccine, in combination with an anti-PD-1 immune-checkpoint inhibitor, has successfully inhibited the growth of pre-established ovarian cancer in animal models. The study demonstrated complete responses in nearly all treated animals, extending their survival beyond 80 days post-vaccination. This development highlights the versatility of Defence's ARM-X platform, which previously showed effectiveness against solid T-cell lymphoma, melanoma, and pancreatic cancer. The ARM-X vaccine requires lower antigen amounts, making it adaptable to patients' needs regardless of cancer type. The company is also testing ARM-X for colon cancer to set targets for upcoming Phase I-IIa trials.

Defence Therapeutics' Chief Scientific Officer, Dr. Moutih Rafei, discussed the company's Accum platform for cancer treatments on Money Talk Radio with Ellis Martin. The interview highlighted Defence's innovative approach in the field of immune-oncology, focusing on the enhancement of vaccine efficacy and drug delivery systems. The Accum platform aims to improve the targeting and effectiveness of cancer treatments, potentially transforming the landscape of oncology therapies. The discussion emphasized the platform's potential to make significant advances in cancer treatment.

Listeners can access the full interview on Money Talk Radio's website.

Defence Therapeutics (CSE: DTC) (OTCQB: DTCFF) is set to participate in the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting on June 11, 2024, in Toronto. This event is a key gathering for professionals involved in nuclear and molecular imaging. Defence will showcase AccuTRIC™, a novel Radio-Immuno-Conjugate developed with Orano Support SAS. AccuTRIC™ leverages Defence's AccuTOX® to enhance the treatment of hard-to-treat cancers. The technology aims to improve radiotherapy by using Auger electron emitter elements, which minimize damage to healthy tissues while maximizing therapeutic effects.

Defence Therapeutics announced the publication of a peer-reviewed study on AccuTOX, an anti-cancer molecule, in the Journal of Translational Medicine. The study details how AccuTOX synergizes with immune-checkpoint inhibitors to disrupt tumor growth. AccuTOX, derived from the Accum platform, shows enhanced killing potency, versatility, and ease of manufacturing. It induces immunogenic cell death and enhances cancer cell visibility to the immune system. The compound targets multiple cancer cell lines and has shown no apparent toxicity in animal models. Defence is initiating a Phase I trial and has submitted a CTA application to Health Canada.

Defence Therapeutics, a biopharmaceutical firm, announced the issuance and allowance of multiple patents across several Patent Families. The US Patent Office allowed application no. 18/169,440, enhancing the company's vaccine platform technology, Accum®, known for boosting antigen presentation. Recent pre-clinical studies using Defence's ARM-002™ vaccine showed significant antitumor responses, paving the way for Phase I trials.

Another patent in Australia for Defence's ADC platform was granted on February 1, 2024, further protecting Accum® and its variants, and adding to existing patents in the US, Japan, and Israel. Additionally, patents for Defence's vaccine platform technology were granted in Canada and Australia, with a Japanese patent expected soon. These patents cover methods and compositions for enhancing antigen immunogenicity.

CEO Mr. Plouffe highlighted the importance of these patents in Defence's mission to innovate and improve human health. The company is accelerating the examination of remaining applications via the Patent Prosecution Highway (PPH) program.

Defence Therapeutics Inc. announces successful completion of a pre-clinical vaccination trial using its ARM-002TM vaccine against pancreatic cancer, showing therapeutic effectiveness when combined with an immune-checkpoint inhibitor. Results reveal potent vaccine efficacy with tumor growth inhibition, positioning the company to target 'hard-to-treat' cancers like pancreatic cancer. The pancreatic cancer market is projected to exceed USD 36 billion by 2036.